Cancer therapy with vaccination using HLA-A24-restricted peptide from URLC10:a phase I study in patient with unresectable esophageal cancer

Cancer therapy with vaccination using HLA-A24-restricted peptide from URLC10:a phase I study in patient with unresectable esophageal cancer - URLC10 peptide vaccination: a phase I study in patients with unresectable esophageal cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000955

Enrollment

Registered

2007-12-24

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable esophageal cancer

Interventions

Vaccination using epitope peptide from URLC10

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance statas 0-2 HLA-A24 No responce to radiation, 5-FU+CDDP etc.

Exclusion criteria

Exclusion criteria: pregnancy uncontroled infection uncontroled cerebral metastasis etc

Design outcomes

Primary

Measure	Time frame
safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026